
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. is witnessing steady growth in its EsoGuard test volume, with a 2% year-over-year increase recorded in 3Q25, reflecting rising demand for its services. The company is expanding insurance coverage for EsoGuard, particularly with Medicare, which is expected to drive substantial revenue growth as it capitalizes on the increasing test volume and broader market accessibility. Additionally, positive developments from the MolDX CAC meeting indicate potential for favorable Medicare coverage decisions, further enhancing Lucid Diagnostics' financial prospects and market position.
Bears say
Lucid Diagnostics Inc. experienced a missed consensus revenue in the third quarter of 2025, contributing to a negative outlook for the company's stock. The company reported a pro forma net loss of $10.3 million, exceeding both its own estimates and consensus expectations, alongside a stable cash burn that resulted in approximately $47 million of pro forma cash remaining. Significant risks confront Lucid, including slow adoption rates for its EsoGuard product, potential insurance reimbursement challenges, and competitive pressures from emerging tests, all of which could adversely affect the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares